Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate

Authors

Soumyajit Roy, Rush University
Jeff M Michalski, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

11-10-2023

Volume

41

Issue

32

First Page

5005

Last Page

5014

Document Type

Open Access Publication

DOI

10.1200/JCO.23.00617

Rights and Permissions

Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Reiter RE, Rettig MB, Nickols NG, Steinberg ML, Valle LF, Ma TM, Farrell MJ, Neilsen BK, Juarez JE, Deng J, Vangala S, Avril N, Jia AY, Zaorsky NG, Sun Y, Spratt D, Kishan AU; Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023 Nov 10;41(32):5005-5014. doi: 10.1200/JCO.23.00617. © 2023 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

Recommended Citation

Roy, Soumyajit; Michalski, Jeff M; and et al., "Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate." Journal of Clinical Oncology. 41, 32. 5005 - 5014. (2023).
https://digitalcommons.wustl.edu/oa_4/3341

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.